Predicted protein targets (top 12)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PRMT5 | O14744 | 1/20 | 0.37 |
| ▸ | WDR77 | Q9BQA1 | 1/20 | 0.37 |
| ▸ | CSF1R | P07333 | 2/20 | 0.35 |
| ▸ | GPR139 | Q6DWJ6 | 4/20 | 0.35 |
| ▸ | KIT | P10721 | 3/20 | 0.35 |
| ▸ | FLT3 | P36888 | 4/20 | 0.34 |
| ▸ | RIPK2 | O43353 | 2/20 | 0.33 |
| ▸ | ADORA3 | P0DMS8 | 1/20 | 0.33 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.32 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.32 |
| ▸ | PKM | P14618 | 1/20 | 0.32 |
| ▸ | HPGD | P15428 | 1/20 | 0.32 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL25206395 | 1.00 | PRMT5 (0.37) | PRMT5WDR77CSF1RGPR139KIT | |
| SCHEMBL25195566 | 0.81 | SMN1; SMN2 (0.33) | KDM4EALDH1A1HPGD | |
| SCHEMBL30461647 | 0.80 | GPR139 (0.37) | PRMT5WDR77CSF1RGPR139KIT | |
| SCHEMBL25197715 | 0.80 | GPR139 (0.37) | PRMT5WDR77CSF1RGPR139KIT | |
| SCHEMBL25196657 | 0.80 | GPR139 (0.39) | PRMT5WDR77CSF1RGPR139KIT | |
| SCHEMBL25294274 | 0.80 | TAAR1 (0.44) | PRMT5WDR77CSF1RKIT | |
| SCHEMBL30429663 | 0.78 | CSF1R (0.38) | PRMT5WDR77CSF1RGPR139KIT | |
| SCHEMBL25209286 | 0.78 | CSF1R (0.38) | PRMT5WDR77CSF1RGPR139KIT | |
| SCHEMBL23114698 | 0.75 | FLT3 (0.42) | PRMT5WDR77CSF1RGPR139KIT | |
| SCHEMBL25199208 | 0.72 | PRMT5 (0.40) | PRMT5WDR77CSF1RGPR139KIT |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-4423060-A2 | PSYCHOPLASTOGENIC N-SUBSTITUTED INDOLES | Terran Biosciences, Inc. (US) | 2024-09-04 | — | — | EP | disclosed |
| US-20230159456-A1 | N-SUBSTITUTED INDOLES | TERRAN BIOSCIENCES INC (US) | 2023-05-25 | — | — | US | disclosed |
| WO-2023077127-A2 | N-SUBSTITUTED INDOLES | TERRAN BIOSCIENCES, INC. (US) | 2023-05-04 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20230159456-A1 | N-SUBSTITUTED INDOLES | TPH2, TPH1, AANAT | PRMT5 661/4885WDR77 2728/4885CSF1R 4254/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.